Molecular radiobiology: The state of the art

Journal of Clinical Oncology

Volumn , Issue 26, 2014, Pages 2871-2878

  Giaccia, Amato J ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOSENSITIZING AGENT;

CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL FUNCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; NUCLEAR REPROGRAMMING; RADIOBIOLOGY; REVIEW; TISSUE INJURY; GENETICS; NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE; PROCEDURES;

HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; RADIOBIOLOGY;

EID: 84907017990     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.2776     Document Type: Review

References (75)

1. Druker BJ: Translation of the Philadelphia chromosome into therapy for CML. Blood 112:4808-4817, 2008
2. Macdermed DM, Weichselbaum RR, Salama JK: A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol 98:202-206, 2008
3. Sklar MD: The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239:645-647, 1988
4. McKenna WG, Weiss MC, Endlich B, et al: Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res 50:97-102, 1990
5. McKenna WG, Weiss MC, Bakanauskas VJ, et al: The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 18:849-859, 1990
6. Zhang FL, Casey PJ: Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269, 1996
7. Kohl NE, Wilson FR, Mosser SD, et al: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A 91:9141-9145, 1994
8. Hahn SM, Bernhard EJ, Regine W, et al: A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 8:1065-1072, 2002
9. Haas-Kogan DA, Banerjee A, Poussaint TY, et al: Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol 13:298-306, 2011
10. Harari PM, Huang SM: Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11:281-289, 2001
11. Nasu S, Ang KK, Fan Z, et al: C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 51:474-477, 2001
12. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
13. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28, 2010
14. Mehra R, Cohen RB, Burtness BA: The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncology 6:742-750, 2008
15. Morris ZS, Harari PM: Interaction of radiation therapy with molecular targeted agents. J Clin Oncol 32:2886-2893, 2014
16. Bernier J, Hall EJ, Giaccia A: Radiation oncology: A century of achievements. Nat Rev Cancer 4:737-747, 2004
17. Rischin D, Peters LJ, OSullivan B, et al: Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28:2989-2995, 2010
18. Jameson MB, Rischin D, Pegram M, et al: A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol 65:791-801, 2010
19. Rischin D, Hicks RJ, Fisher R, et al: Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24:2098-2104, 2006
20. Vaupel P: Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14:198-206, 2004
21. Secomb TW, Hsu R, Ong ET, et al: Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 34:313-316, 1995
22. Gagnon G, Regoli D, Rioux F: Studies on the mechanism of action of various vasodilators. Br J Pharmacol 70:219-227, 1980
23. Snyder SA, Lanzen JL, Braun RD, et al: Simultaneous administration of glucose and hyperoxic gas achieves greater improvement in tumor oxygenation than hyperoxic gas alone. Int J Radiat Oncol Biol Phys 51:494-506, 2001
24. Zannella VE, Dal Pra A, Muaddi H, et al: Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res 19:6741-6750, 2013
25. Song CW, Lee H, Dings RP, et al: Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep 2:362, 2012
26. Storozhuk Y, Hopmans SN, Sanli T, et al: Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 108:2021-2032, 2013
27. Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302, 2009
28. Skinner HD, McCurdy MR, Echeverria AE, et al: Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52: 1002-1009, 2013
29. Ferro A, Goyal S, Kim S, et al: Evaluation of diabetic patients with breast cancer treated with metformin during adjuvant radiotherapy. Int J Breast Cancer 2013:659723, 2013
30. Bedogni B, Powell MB: Skin hypoxia: A promoting environmental factor in melanomagenesis. Cell Cycle 5:1258-1261, 2006
31. Muaddi H, Chowdhury S, Vellanki R, et al: Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin. Radiother Oncol 108:446-450, 2013
32. Campbell RK, White JR Jr, Saulie BA: Metformin: A new oral biguanide. Clin Ther 18:360-371, 1996
33. Lin X, Zhang F, Bradbury CM, et al: 2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res 63:3413-3417, 2003
34. Coleman MC, Asbury CR, Daniels D, et al: 2-Deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med 44:322-331, 2008
35. Dwarkanath BS, Zolzer F, Chandana S, et al: Heterogeneity in 2-deoxy-D-glucose-induced modifications in energetics and radiation responses of human tumor cell lines. Int J Radiat Oncol Biol Phys 50:1051-1061, 2001
36. Sinthupibulyakit C, Grimes KR, Domann FE, et al: p53 is an important factor for the radiosensitization effect of 2-deoxy-D-glucose. Int J Oncol 35:609-615, 2009
37. Mohanti BK, Rath GK, Anantha N, et al: Improving cancer radiotherapy with 2-deoxy-D-glucose: Phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys 35:103-111, 1996
38. Singh D, Banerji AK, Dwarakanath BS, et al: Optimizing cancer radiotherapy with 2-deoxy-dglucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol 181: 507-514, 2005
39. Chan DA, Sutphin PD, Nguyen P, et al: Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 3:94ra70, 2011
40. Kennedy KM, Dewhirst MW: Tumor metabolism of lactate: The influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 6:127-148, 2010
41. Halestrap AP, Wilson MC: The monocarboxylate transporter family: Role and regulation. IUBMB Life 64:109-119, 2012
42. Sonveaux P, Vegran F, Schroeder T, et al: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930-3942, 2008
43. Miranda-Goncalves V, Honavar M, Pinheiro C, et al: Monocarboxylate transporters (MCTs) in gliomas: Expression and exploitation as therapeutic targets. Neuro Oncol 15:172-188, 2013
44. Krause DS, Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187, 2005
45. Verellen D, De Ridder M, Linthout N, et al: Innovations in image-guided radiotherapy. Nat Rev Cancer 7:949-960, 2007
46. Eisbruch A: Intensity-modulated radiation therapy in the treatment of head and neck cancer: Nature clinical practice. Oncology 2:34-39, 2005
47. Kastan MB: DNA damage responses: Mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol Cancer Res 6:517-524, 2008
48. Guo K, Shelat AA, Guy RK, et al: Development of a cell-based, high-throughput screening assay for ATM kinase inhibitors. J Biomol Screening 19:538-546, 2014
49. Chan DA, Giaccia AJ: Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 10:351-364, 2011
50. Ashworth A: A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785-3790, 2008
51. Bindra RS, Schaffer PJ, Meng A, et al: Downregulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 24:8504-8518, 2004
52. Chan N, Koritzinsky M, Zhao H, et al: Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 68:605-614, 2008
53. Chan N, Bristow RG: "Contextual" synthetic lethality and/or loss of heterozygosity: Tumor hypoxia and modification of DNA repair. Clin Cancer Res 16:4553-4560, 2010
54. Higgins GS, Prevo R, Lee YF, et al: A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown. Cancer Res 70:2984-2993, 2010
55. Spencer CM, Goa KL: Amifostine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 50:1001-1031, 1995
56. Weiss JF, Landauer MR: Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology 189:1-20, 2003
57. Komarov PG, Komarova EA, Kondratov RV, et al: A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285:1733-1737, 1999
58. Kirsch DG, Santiago PM, di Tomaso E, et al: p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science 327:593-596, 2010
59. Burdelya LG, Krivokrysenko VI, Tallant TC, et al: An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320:226-230, 2008
60. Paris F, Fuks Z, Kang A, et al: Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293:293-297, 2001
61. Taniguchi CM, Miao YM, Diep AN, et al: PHD inhibition mitigates and protects against radiationinduced gastrointestinal toxicity via HIF2. Sci Transl Med 6:236-264, 2014
62. Yan L, Colandrea VJ, Hale JJ: Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: Small moleculebased therapeutics for anemia. Expert Opin Ther Pat 20:1219-1245, 2010
63. Salama JK, Milano MT: Radical irradiation of extracranial oligometastases. J Clin Oncol 32:2902-2912, 2014
64. Benderitter M, Caviggioli F, Chapel A, et al: Stem cell therapies for the treatment of radiationinduced normal tissue side effects. Antioxid Redox Signal 21:338-355, 2014
65. Guha C, Sharma A, Gupta S, et al: Amelioration of radiation-induced liver damage in partially hepatectomized rats by hepatocyte transplantation. Cancer Res 59:5871-5874, 1999
66. Krause P, Wolff HA, Rave-Frank M, et al: Fractionated external beam radiotherapy as a suitable preparative regimen for hepatocyte transplantation after partial hepatectomy. Int J Radiat Oncol Biol Phys 80:1214-1219, 2011
67. Hughes RD, Mitry RR, Dhawan A: Current status of hepatocyte transplantation. Transplantation 93:342-347, 2012
68. Burnette B, Weichselbaum RR: Radiation as an immune modulator. Semin Radiat Oncol 23:273-280, 2013
69. Sharma P, Wagner K, Wolchok JD, et al: Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat Rev Cancer 11:805-812, 2011
70. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264, 2012
71. Postow MA, Callahan MK, Barker CA, et al: Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925-931, 2012
72. Hiniker SM, Chen DS, Knox SJ: Abscopal effect in a patient with melanoma. N Engl J Med 366:2035, 2012
73. Stamell EF, Wolchok JD, Gnjatic S, et al: The abscopal effect associated with a systemic antimelanoma immune response. Int J Radiat Oncol Biol Phys 85:293-295, 2013
74. Seung SK, Curti BD, Crittenden M, et al: Phase 1 study of stereotactic body radiotherapy and interleukin-2: Tumor and immunological responses. Sci Transl Med 4:137ra74, 2012
75. Formenti SC, Demaria S: Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst 105:256-265, 2013